Adis Journals
2 files

Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone

posted on 2020-02-26, 11:50 authored by Krishnan Ramaswamy, Stanislav Lechpammer, Jack Mardekian, Ahong Huang, Neil M. Schultz, Rickard Sandin, Li Wang, Onur Baser, Daniel J. George

Provide enhanced digital features for this article

This Figshare page contains a summary slide and plain language summary. If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact

The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.

Other enhanced features include, but are not limited to:
• Slide decks
• Videos and animations
• Audio abstracts
• Audio slides


Pfizer Inc. (New York, NY, USA), and Astellas Pharma, Inc. (Northbrook, IL, USA)